Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.

Lawrence F Eichenfield Elaine C Siegfried Pearl KwongMark McBrideJayson RiegerDavid GloverCynthia WillsonMatthew DavidsonPatrick BurnettMelissa Olivadoti

Published in: American journal of clinical dermatology (2021)

ClinicalTrials.gov identifiers: NCT03377790 (first posted 19 December 2017) and NCT03377803 (first posted 19 December 2017). Video abstract: Pooled Results of Two Randomized Phase III Trials Evaluating VP 102, a Drug Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum (MP4 131293 KB).

Keyphrases

phase iii
open label
double blind
clinical trial
placebo controlled
phase ii
study protocol
combination therapy